NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
